THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Uni-Bio Science Group Limited ("**Company**"), you should at once hand or forward this circular and the accompanying form of proxy to the purchaser, the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

GRANT OF OPTIONS UNDER SHARE OPTION SCHEME AND NOTICE OF EXTRAORDINARY GENERAL MEETING

A notice convening the EGM to be held at 10:30 a.m. on Wednesday, 19 August 2026 at Unit 502, 5/F., No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong, is set out on pages EGM-1 to EGM-3 of this circular. A form of proxy for use by the Shareholders at the EGM is published on the website of the Stock Exchange and that of the Company.

Whether or not you are able to attend and vote at the EGM, you are requested to complete and return the accompanying form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by 10:30 a.m. on Monday, 17 August 2026 or not less than 48 hours before the time appointed for holding any adjourned EGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

This circular will remain on the "Latest Listed Company Information" page of the Stock Exchange's website at www.hkexnews.hk for a minimum period of seven days from the date of its publication and on the Company's website at https://www.uni-bioscience.com.

* *For identification purposes only*

30 July 2026

CONTENTS

Page

Definitions 1

Letter from the Board 3

Notice of EGM EGM-1

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"Articles"	the articles of association of the Company as amended from time to time
"associate(s)"	has the meaning ascribed thereto in the Listing Rules
"Board"	the board of Directors
"Business Day"	any day on which the Stock Exchange is open for the business of dealing in securities
"close associate(s)"	has the meaning ascribed thereto in the Listing Rules
"Company"	Uni-Bio Science Group Limited 聯康生物科技集團有限公司*, a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on Stock Exchange
"connected person(s)"	has the meaning ascribed thereto in the Listing Rules
"core connected person(s)"	has the meaning ascribed thereto in the Listing Rules
"Date of Grant"	24 June 2026, being the date of offer of the Grant of the Options as announced by the Company
"Director(s)"	the director(s) of the Company
"Dr. Wen"	Dr. Wen Yalei, chief operating officer of the Company and an executive Director
"EGM"	the extraordinary general meeting of the Company to be held at 10:30 a.m. on Wednesday, 19 August 2026 at Unit 502, 5/F., No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong, the notice of which is set out on pages EGM-1 to EGM-3 of this circular
"FY2028"	the financial year ending 31 December 2028
"Grant"	the conditional grant of the Options to the Grantees which entitle them to subscribe a maximum of 300,000,000 Shares
"Grantee(s)"	collectively, Mr. Leung Kingsley, Mr. Zhao Zhi Gang, Dr. Wen Yalei and Mr. Cheng Yu-Jen, and each a "Grantee"
"Group"	the Company and its subsidiaries

* *For identification purposes only*

"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Latest Practicable Date"	24 July 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained herein
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Mr. Cheng"	Mr. Cheng Yu-Jen, chief business officer of the Company
"Mr. Leung"	Mr. Leung Kingsley, chairman of the Board of the Company and an executive Director
"Mr. Zhao"	Mr. Zhao Zhi Gang, chief executive officer of the Company and an executive Director
"Option(s)"	any option(s) to be granted to Grantee(s) to subscribe for new Share(s) under the Share Option Scheme
"PRC"	the People's Republic of China, and for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Remuneration Committee"	the remuneration committee of the Board
"Share Option Scheme"	the share option scheme of the Company approved and adopted by the Company at the extraordinary general meeting of the Company held on 26 May 2026
"Share Registrar"	branch share registrar and transfer office of the Company in Hong Kong for the time being
"Share(s)"	ordinary share(s) of HK$0.01 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subscription Price"	the price per Share at which a Grantee shall pay for the subscription of the Shares on the exercise of an Option
"treasury shares"	Shares repurchased and held by the Company in treasury as treasury shares in accordance with the Articles
"%"	per cent.

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

Executive Directors:
Mr. Leung Kingsley *(Chairman)*
Mr. Chen Dawei *(Vice-chairman)*
Mr. Zhao Zhi Gang *(Chief executive)*
Dr. Wen Yalei

Non-executive Directors:
Mr. Yau Kwok Wing Tony
Ms. Zhang Qing

Independent Non-executive Directors:
Mr. Chow Kai Ming
Mr. Ren Qimin
Mr. Ma Qingshan

Registered office:
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Head office and principal place of business in Hong Kong:
Unit 502, 5/F
No. 20 Science Park East Avenue
Hong Kong Science Park
Shatin, New Territories, Hong Kong

30 July 2026

To the Shareholders

Dear Sir or Madam

GRANT OF OPTIONS UNDER SHARE OPTION SCHEME

1. INTRODUCTION

Reference is made to the announcement of the Company dated 24 June 2026 in relation to, among other things, the Grant of Options to Grantees. The purpose of this circular is to provide you with information in respect of the resolutions to be proposed to seek approval of the Shareholders in respect of the Grant of Options to the Grantees.

2. GRANT OF OPTIONS UNDER SHARE OPTION SCHEME

On 24 June 2026, the Board resolved to conditionally grant Options carrying the rights to subscribe for up to a total of 300,000,000 new Shares upon exercise to the Grantees under the Share Option Scheme at an exercise price of HK$0.09 per Share, subject to acceptance by the

* *For identification purposes only*

relevant Grantees. As at Latest Practicable Date, each Grantee has confirmed his acceptance of the Options conditionally granted to him. The Grant will be subject to approval by the independent Shareholders at the EGM.

Save for the maximum number of Shares that the relevant Grantee may subscribe pursuant to the exercise of the Options granted to such Grantee, the terms and conditions of all Options conditionally granted on 24 June 2026 are the same, details of the Options granted to the Grantees are set out below:

Date of Grant	:	24 June 2026
Exercise price of Options granted	:	HK$0.09 per Share, representing the highest of: (i) the closing price of HK$0.08 per Share as stated in the Stock Exchange's daily quotation sheet on the Date of Grant; (ii) the average closing price of HK$0.09 per Share as stated in the Stock Exchange's daily quotation sheets for the five consecutive business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share on the Date of Grant.
Exercise period of the Options	:	Subject to the fulfilment of the exercise conditions as detailed below, the Grantee may exercise the Options (to the extent vested) up to the tenth anniversary of the date of grant. Any unexercised portion will automatically lapse upon expiry of the 10-year term or otherwise in accordance with the terms of the Share Option Scheme.
Vesting schedule of the Options	:	Vesting will occur in accordance with the following schedule: (1) one-third of the Options (subject to adjustment(s)) shall be vested to a Grantee on the first anniversary of the Date of Grant. The date on which such vesting occurs is hereinafter referred to as the "First Vesting Date"; (2) one-third of the Options as at the Date of Grant (subject to adjustment(s)) shall be vested on the first anniversary of the First Vesting Date; and

		(3) the remaining one-third of the Options as at the Date of Grant (subject to adjustment(s)) shall be vested on the second anniversary of the First Vesting Date.
Consideration for the grant of the Options	:	HK$1.00 to be paid by each Grantee upon acceptance of the Options granted.
Performance targets and exercise conditions	:	The exercise of the Options under the grant is subject to the fulfilment of the conditions specified below: (1) the Company records audited consolidated revenue of not less than HK$1,000,000,000 in its audited consolidated financial statements for any full financial year ending on or before 31 December 2028; and (2) in the same financial year, the Company records audited consolidated profit for the year of not less than HK$100,000,000 in its audited consolidated financial statements for that financial year. The above exercise conditions constitute performance targets attached to the Options. If the conditions are not met in any financial year on or before the date immediately following the publication of the Company's preliminary announcement for FY2028, all Options (whether or not vested) shall not be exercisable and the Options granted hereunder shall lapse automatically.
Clawback mechanism	:	There is no clawback mechanism attached to the share options. Without prejudice to the terms and conditions of the Share Option Scheme, the Options granted to a Grantee shall lapse if such Grantee ceases to be a qualifying participant of the Share Option Scheme by reason of termination of employment for, among other matters, persistent or serious misconduct, or has committed any act of bankruptcy, or has become insolvent, or has made any arrangement or composition with his creditors generally, or has been convicted of any criminal offence.

		The Remuneration Committee of the Company considers that a specific clawback mechanism is not necessary as the lapse and cancellation of the Options granted under various scenarios has already been provided for under the rules of the Share Option Scheme, which would adequately safeguard the interests of the Company and its Shareholders.
Financial assistance	:	No financial assistance shall be provided by the Group to the Grantees to facilitate the purchase/subscription of Shares under the Share Option Scheme.

A total of 300,000,000 Options (upon exercise in full and subject to adjustment in accordance with the Share Option Scheme) were granted to the Grantees, details of which are as follows:

Grantees	**Position**	**Number of Options granted**	**Approximate % to the total issued share capital of the Company as at the Latest Practicable Date**
Mr. Leung Kingsley	Chairman of the Board and executive Director	90,000,000	1.51%
Mr. Zhao Zhi Gang	Chief executive officer and executive Director	90,000,000	1.51%
Dr. Wen Yalei	Chief operating officer and executive Director	60,000,000	1.00%
Mr. Cheng Yu-Jen	Chief business officer	60,000,000	1.00%
		300,000,000	5.02%

No Option has been granted by the Company to any of the Grantees within the 12-month period prior to the Date of Grant.

The number of Options granted to each Grantee was determined by the Board, following the recommendation of the Remuneration Committee, with reference to a number of factors, including the roles, responsibilities and seniority of each Grantee within the Group, his past and expected future contribution to the business development, operations and financial performance of the Group, prevailing market practice for share incentive grants by comparable companies in the industry in which the Group operates, and the objective of aligning the long-term interests of the Grantees with those of the Company and the Shareholders as a whole. Having regard to the more extensive management responsibilities and strategic decision-making roles of Mr. Leung, as chairman of the Board, and Mr. Zhao, as chief executive officer, as compared with the more operationally-focused roles of Dr. Wen, as chief operating officer, and Mr. Cheng, as chief business officer and who is the shortest in service amongst the four Grantees, a lower number of Options was granted to each of Dr. Wen and Mr. Cheng than to Mr. Leung and Mr. Zhao.

The Remuneration Committee considers that the aggregate size of the Grant, representing approximately 5.02% of the total Shares in issue (excluding treasury shares), is fair and reasonable and in the interests of the Company and the Shareholders as a whole, having regard to, among other things: (i) the fact that the Grant will utilise only approximately half of the initial scheme mandate limit under the Share Option Scheme, leaving 297,122,814 Shares available for future grants under the Share Option Scheme; (ii) the vesting schedule of the Options (which will vest in tranches over a period of three years) and the exercise conditions attached to the Options, which are designed to align the interests of the Grantees with the long-term performance of the Group and the interests of the Shareholders as a whole, rather than short-term Share price movements; (iii) the fact that the Grant is a one-off grant, and that no options have been granted to any of the Grantees in the 12-month period immediately preceding the Date of Grant; and (iv) the Group's overall business objectives and future development plan, and the Remuneration Committee's assessment that the Grantees, having regard to their respective roles and responsibilities within the Group, are well placed to assist the Group in achieving the performance targets set out in the exercise conditions.

In this regard and solely for illustration purposes only, the Remuneration Committee noted that, if the exercise conditions are fulfilled, the Group's audited consolidated revenue and audited consolidated profit for the relevant financial year are expected to represent an increase of approximately 107% and approximately 88%, respectively, as compared with the Group's average audited consolidated revenue and average audited consolidated profit, respectively, for the five financial years ended 31 December 2021 to 31 December 2025, and considered that the Grantees have contributed, and are expected to continue to contribute, to such growth momentum.

The Shares to be allotted upon exercise of the Options shall rank pari passu with the Shares then in issue (excluding treasury shares) in all respects and shall have the same voting rights, rights in respect of any dividend or other distributions paid or made on or after the date of issue, rights of transfer and other rights, including those arising on liquidation of the Company as attached to the Shares in issue (excluding treasury shares) on the date of such allotment and will be subject to all the provisions of the Articles of Association and the laws of the Cayman Islands for the time being in force.

The Options themselves do not carry any right to vote in general meeting of the Company, nor any dividend, transfer or any other rights, including those arising on liquidation of the Company, prior to them being exercised and the underlying Shares being issued.

None of the Directors is the trustee of the Share Option Scheme, nor do they have any direct or indirect interest in the trustee of the Share Option Scheme.

3. REASONS FOR AND BENEFITS OF THE GRANT

The Grant aims to align the interests of the Grantees with those of the Group through ownership of Shares and incentivise the Grantees to remain with the Group, and to motivate and encourage them to work towards enhancing the Group's corporate value and achieving the long-term objectives for the benefit of the Group as a whole.

4. LISTING RULES IMPLICATIONS

Pursuant to Rule 17.04(1) of the Listing Rules, any grant of Options to a Director, chief executive or substantial Shareholder under the Share Option Scheme must be approved by independent non-executive Directors. The independent non-executive Directors have approved the Grant, in accordance with the said Rule 17.04(1).

Pursuant to Rule 17.03D of the Listing Rules and the terms of the Share Option Scheme, if the grant of options to a Grantee would result in the Shares in issue (excluding treasury shares) and to be issued under all options granted to such Grantee by the Company during the 12-month period up to and including the date of grant (excluding any Options which have lapsed under the terms of the Share Option Scheme) in excess of 1% of the relevant class of Shares of the Company in issue (excluding treasury shares) ("**1% Individual Limit**"), then the Company must convene a separate general meeting to seek Shareholders' approval (at which the Grantee and its close associates or, in the case of the Grantee who is a connected person, its associates must abstain from voting).

In addition, pursuant to Rule 17.04(3) of the Listing Rules, if the grant of Options to an independent non-executive Director or a substantial shareholder or any of their respective associates would result in the total number of Shares of the Company in issue (excluding treasury shares) and to be issued under all Options granted (excluding Options or awards lapsed under the terms of the Share Option Scheme) during the 12-month period up to the date of grant of Options to such person exceeding in aggregate 0.1% of the Shares of the relevant class in issue ("**0.1% Limit**"), then such proposed grant of Options shall be approved by the Shareholders in a general meeting in the manner described in Rule 17.04(4).

Mr. Leung, Mr. Zhao and Dr. Wen, each being an executive Director, have abstained from voting on the Board resolutions for considering and approving the Grant. Save for the aforesaid, none of the Directors has a material interest in the resolutions approving the Grant.

Out of the four Grantees, Mr. Leung, Mr. Zhao and Dr. Wen, each being an executive Director, are core connected persons of the Company. Mr. Leung is also an associate of the substantial shareholder of the Company. According to Rule 17.04(4) of the Listing Rules, where the grant of an option or award is to a director, the grantee, his/her associates and all core connected persons of the listed issuer must abstain from voting in favour at the relevant general meeting to be convened. As at the Latest Practicable Date, to the best knowledge of the Directors after making reasonable enquiry, all core connected persons of the Company (inclusive of Mr. Leung, Mr. Zhao and Dr. Wen and their respective close associates) are entitled to exercise control over the voting rights in respect of an aggregate of 1,929,339,464 Shares, representing approximately 32.31% of the total number of Shares in issue (excluding treasury shares). All such core connected persons of the Company are thus required to abstain from voting in favour on all resolutions in respect of the Grant, namely ordinary resolutions numbered 1 to 4 in the notice of the EGM set out on pages EGM-1 to EGM-3 of this circular.

Save as disclosed above, as at the Latest Practicable Date, none of the Shareholders who are required to abstain from voting in favour of the resolution approving the Grant have given the Company notice of their intention to vote against the resolution at the EGM.

5. NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

As of the Latest Practicable Date and following the Grant, 297,122,814 Shares underlying the share options under the Share Option Scheme will be available for future grants under the existing scheme mandate limit.

6. EGM AND PROXY ARRANGEMENT

The notice of the EGM is set out on pages EGM-1 to EGM-3 of this circular. At the EGM, ordinary resolutions will be proposed to approve the proposed Grant to the Grantee. In compliance with the Listing Rules, all resolutions will be voted on by way of a poll at the EGM. An announcement will be made by the Company following the conclusion of the EGM to inform the Shareholders of the poll results of the EGM.

A form of proxy for use at the EGM is published on the website of the Stock Exchange and that of the Company. Whether or not you are able to attend and vote at the EGM, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by 10:30 a.m. on Monday, 17 August 2026 or not less than 48 hours before the time appointed for holding any adjourned EGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

Closure of register of members

To ascertain a Shareholder's entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Friday, 14 August 2026 to Wednesday, 19 August 2026 (both days inclusive), during which no transfer of Shares will be registered. The record date for determining the entitlement to attend and vote at the EGM is 19 August 2026.

In order to qualify for the entitlement to attend and vote at the EGM, all transfers of Shares, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Thursday, 13 August 2026.

7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company.

The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

8. RECOMMENDATION

The Board (including all the independent non-executive Directors, but save and except Mr. Leung, Mr. Zhao and Dr. Wen) is of the view that the terms of the Grant are fair and reasonable and the Grant is in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board (including all the independent non-executive Directors, but save and except Mr. Leung, Mr. Zhao and Dr. Wen) recommends the Shareholders to vote in favour of the ordinary resolutions in relation to the Grant to be proposed at the EGM.

9. GENERAL INFORMATION

The English text of this circular shall prevail over the Chinese text for the purpose of interpretation.

Yours faithfully,
On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman and Executive Director

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting ("**EGM**") of Uni-Bio Science Group Limited ("**Company**") will be held at 10:30 a.m. on Wednesday, 19 August 2026 at Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong to consider and, if thought fit, pass the following resolutions as ordinary resolutions:

ORDINARY RESOLUTIONS

1. "**THAT** the conditional grant of the share options ("**Options**") carrying the rights to subscribe for up to 90,000,000 new shares of the Company (each, a "**Share**") to Mr. Leung Kingsley, an executive director of the Company and the chairman of the board of directors of the Company, under the share option scheme approved and adopted by the Company at a general meeting held on 26 May 2026 ("**Share Option Scheme**") at an exercise price of HK$0.09 per Share on the terms and conditions set out in the circular of the Company dated 30 July 2026 ("**Circular**") be and is hereby approved and that any one director of the Company ("**Director**") be and is hereby authorised to do all such acts and/or execute all such documents as may be necessary or expedient in order to give effect to the foregoing."

2. "**THAT** the conditional grant of the Options carrying the rights to subscribe for up to 90,000,000 Shares to Mr. Zhao Zhi Gang, an executive director of the Company and the chief executive officer of the Company, under the Share Option Scheme at an exercise price of HK$0.09 per Share on the terms and conditions set out in the Circular be and is hereby approved and that any one Director be and is hereby authorised to do all such acts and/or execute all such documents as may be necessary or expedient in order to give effect to the foregoing."

3. "**THAT** the conditional grant of the Options carrying the rights to subscribe for up to 60,000,000 Shares to Dr. Wen Yalei, an executive director of the Company and the chief operating officer of the Company, under the Share Option Scheme at an exercise price of HK$0.09 per Share on the terms and conditions set out in the Circular be and is hereby approved and that any one Director be and is hereby authorised to do all such acts and/or execute all such documents as may be necessary or expedient in order to give effect to the foregoing."

4. "**THAT** the conditional grant of the Options carrying the rights to subscribe for up to 60,000,000 Shares to Mr. Cheng Yu-Jen, the chief business officer of the Company, under the Share Option Scheme at an exercise price of HK$0.09 per Share on the terms and conditions set out in the Circular be and is hereby approved and that any one Director be and is hereby authorised to do all such acts and/or execute all such documents as may be necessary or expedient in order to give effect to the foregoing."

Yours faithfully
On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman and Executive Director

Hong Kong, 30 July 2026

Registered office:
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Head office and principal place of business in Hong Kong:
Unit 502, 5/F
No. 20 Science Park East Avenue
Hong Kong Science Park
Shatin, New Territories, Hong Kong

Notes:

1. In order to ascertain the entitlement to attend and vote at the meeting convened by the above notice ("**EGM**"), the register of members of the Company will be closed from Friday, 14 August 2026 to Wednesday, 19 August 2026, both days inclusive, during which period no transfer of Shares of the Company will be registered. The record date for determining the entitlement to attend and vote at the EGM is 19 August 2026. In order to qualify for the entitlement to attend and vote at the EGM, all transfer documents of Shares accompanied by the relevant shares certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by 4:30 p.m. on Thursday, 13 August 2026 for registration.

2. A member of the Company entitled to attend and vote at the EGM shall be entitled to appoint another person as his/her/its proxy to attend and vote instead of him/her/it. A member who is the holder of two or more Shares of the Company may appoint more than one proxy to represent him/her/it and vote on his/her/its behalf at the EGM. A proxy need not be a member of the Company.

3. In the case of joint holders of Shares, any one of such joint holders may vote, either in person or by proxy, in respect of such Share as if he/she/it were solely entitled thereto, but if more than one of such joint holders are present at the EGM, personally or by proxy, that one of the said persons so present whose name stands first in the register in respect of such Shares shall alone be entitled to vote in respect thereof.

4. In order to be valid, the form of proxy must be in writing including electronic or otherwise, as the Board may determine and in the absence of such determination, shall be in writing, which may include electronic writing signed by the appointer or of his attorney duly authorised in writing, or if the appointer is a corporation, either under seal, or signed by an officer or attorney duly authorised, and must be deposited with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (together with the power of attorney or other authority, if any, under which it is signed or a certified copy thereof) by 10:30 a.m., Monday, 17 August 2026 or not less than 48 hours before the time appointed for the holding of the adjourned EGM (as the case may be).

5. Delivery of an instrument appointing a proxy should not preclude a member from attending and voting at the EGM or any adjournment thereof and in such event, the instrument appointing a proxy shall be deemed to be revoked.

6. As required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, all resolutions as set out in this notice to be put to vote at the EGM will be decided by way of poll.

As at the date of this notice, the Board consists of four executive Directors, namely Mr. Leung Kingsley (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer), two non-executive Directors, namely Mr. Yau Kwok Wing Tony and Ms. Zhang Qing and three independent non-executive Directors, namely Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this notice misleading.

This notice will remain on the ''Latest Listed Company Information'' page of the Stock Exchange's website on www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at https://www.uni-bioscience.com.

* *For identification purposes only*